Literature DB >> 32234362

A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.

Lea E Mollon1, Elizabeth J Anderson2, Joni L Dean2, Terri L Warholak2, Ayal Aizer3, Emma A Platt4, Derek H Tang4, Lisa E Davis2.   

Abstract

PIK3CA mutations may have prognostic value for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, representing an important potential target for systemic therapy. Prognostic and predictive values associated with PIK3CA mutations are not well understood. A comprehensive search of PubMed/MEDLINE, EMBASE, Cochrane Central, and conference abstracts was performed for English-language articles published January 1993 through April 2019. Articles were categorized by treatment arms based on experimental and treatment drug classes. Information on progression-free survival (PFS), hazard ratios, overall survival, response rate, and clinical benefit rate was obtained. A total of 17 studies were included. Among those evaluating non-PI3Ki based therapies, 91% showed numerically shorter median PFS, ranging from 1.5 to 19.2 months and 1.8 to 29.6 months for the mutant versus non-mutant subgroups, respectively. Where reported (n = 13 studies), PFS was shorter between those arms offering endocrine monotherapy (range, 1.6-14.7 months) compared with a corresponding targeted therapy + endocrine monotherapy (range, 3.9-29.6 months). Of 5 PI3Ki-based arms comparing PFS, higher median PFS in PIK3CA mutant versus non-mutant cases was demonstrated. PFS was shorter for patients with PIK3CA mutant (range, 1.6-19.2 months) compared with PIK3CA wild-type (range, 1.8-29.6 months) in 10 (71%) of 14 treatment arms reporting PFS. Studies (n = 4) not reporting PFS reported response rate, but there were no clear directional trends. The presence of PIK3CA mutations may be associated with worse clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Clinical outcomes such as PFS may be improved using a combination of PI3Ki-based therapies and endocrine therapies among this population. However, more research is warranted to fully elucidate this association.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiestrogens; Biomarker; PI3K inhibitor; Precision medicine; Somatic mutations

Mesh:

Substances:

Year:  2019        PMID: 32234362     DOI: 10.1016/j.clbc.2019.08.011

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  14 in total

1.  PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy.

Authors:  Yoon Ah Cho; Seung Yeon Ko; Yong Joon Suh; Sanghwa Kim; Jung Ho Park; Hye-Rim Park; Jinwon Seo; Hyo Geun Choi; Ho Suk Kang; Hyun Lim; Ha Young Park; Mi Jung Kwon
Journal:  Curr Oncol       Date:  2022-04-19       Impact factor: 3.109

2.  Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population.

Authors:  Qingfeng Huang; Yang Zhou; Bowen Wang; Yi Zhao; Fengxia Zhang; Bowen Ding
Journal:  BMC Med Genomics       Date:  2022-07-01       Impact factor: 3.622

Review 3.  Pre-PCR Mutation-Enrichment Methods for Liquid Biopsy Applications.

Authors:  Farzaneh Darbeheshti; Fangyan Yu; G Mike Makrigiorgos
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

Review 4.  Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.

Authors:  Chao Dong; Jiao Wu; Yin Chen; Jianyun Nie; Ceshi Chen
Journal:  Front Pharmacol       Date:  2021-03-15       Impact factor: 5.810

5.  Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.

Authors:  Jawaher Al Zeyoudi; Imad El Kebbi; Fatima Al Zaabi; Shahrukh Hashmi
Journal:  Cureus       Date:  2021-12-29

6.  Biosensors for Point Mutation Detection.

Authors:  Hanlin Jiang; Hui Xi; Mario Juhas; Yang Zhang
Journal:  Front Bioeng Biotechnol       Date:  2021-12-15

7.  Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia.

Authors:  Marcus D Goncalves; Azeez Farooki
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

8.  PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come.

Authors:  Leticia De Mattos-Arruda
Journal:  ESMO Open       Date:  2020-08

Review 9.  Targeting the "PVR-TIGIT axis" with immune checkpoint therapies.

Authors:  Laurent Gorvel; Daniel Olive
Journal:  F1000Res       Date:  2020-05-13

10.  A Five-Gene-Pair-Based Prognostic Signature for Predicting the Relapse Risk of Early Stage ER+ Breast Cancer.

Authors:  Na Li; Hao Cai; Kai Song; You Guo; Qirui Liang; Jiahui Zhang; Rou Chen; Jing Li; Xianlong Wang; Zheng Guo
Journal:  Front Genet       Date:  2020-10-29       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.